SCM
DMRA

Soleus Capital Management’s Damora Therapeutics DMRA Stock Holding History

Soleus Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-35,906
Closed -$646K – 89
2023
Q3 		$646K Sell
35,906
-4,094
-10% -$161K 0.06% 85
2023
Q2 		$2.52M Buy
+40,000
New +$2.18M 0.28% 66
2021
Q3 		– Sell
-21,526
Closed -$2.72M – 77
2021
Q2 		$2.72M Sell
21,526
-38,980
-64% -$5.31M 0.42% 42
2021
Q1 		$9.19M Hold
60,506
– – 1.66% 12
2020
Q4 		$18.9M Buy
+60,506
New +$22.5M 2.5% 4

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Soleus Capital Management's DMRA Position: Q4 2023 in Review

Soleus Capital Management sold out of Damora Therapeutics (DMRA) in Q4 2023, closing a stake of 35,906 shares — an estimated $646K sold.

Soleus Capital Management first reported a position in DMRA in Q4 2020 and held it in 5 quarters. The position peaked at $18.9M in Q4 2020. 21 funds tracked by Wall St. Rank hold DMRA as of Q4 2023.

  • Soleus Capital Management reported no remaining Damora Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 35,906 Damora Therapeutics shares in Q4 2023, an estimated $646K.
  • Soleus Capital Management first reported a position in Damora Therapeutics in Q4 2020 and held it in 5 quarters.
  • Soleus Capital Management's Damora Therapeutics position peaked at $18.9M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.